Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma - Wikidata - wikimedia - TriplyDB

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

http://www.wikidata.org/entity/Q36070459

about

An overview of cutaneous T cell lymphomas Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Toll-like receptor agonists partially restore the production of pro-inflammatory cytokines and type I interferon in Sézary syndrome Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.Toll-like receptors and cutaneous melanoma.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.Research Techniques Made Simple: High-Throughput Sequencing of the T-Cell Receptor.Anti-tumor Activity of Toll-Like Receptor 7 Agonists.A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.Profile of differentially expressed Toll-like receptor signaling genes in the natural killer cells of patients with Sézary syndrome.Intratumoral immunotherapy: using the tumor as the remedy.S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86).Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.White paper on microbial anti-cancer therapy and prevention

P2860

Q26740306-C52D85BF-E591-4893-B238-9793073F23F5 Q34516083-38390761-DFE5-4C50-9856-515BC31B8911 Q37029731-8C505D03-C81C-413E-BABC-66D12871D199 Q37688819-AE66FF8B-0FC9-434A-9A99-BBEA43A96959 Q37723390-9DF20A63-F46C-48CC-B528-E6B0A0644762 Q38765889-21E4A467-74F5-4628-87E8-6D62195B7867 Q39023996-6F9463BE-B3BC-402B-9C49-A5CE3CC7B42B Q39055861-6AE9EF29-FD0E-48F9-AD13-4A7FA9F7CA2E Q39323090-A5663766-A34C-4E68-8D6C-24E65645F778 Q39377049-5373C75E-4268-436C-B3FC-8E30431BCAA5 Q41000160-E3197A73-4815-4691-83A5-B4913E727C4A Q47166524-76EB9E08-DA39-4853-AE20-65F19B6E49FE Q47281370-9E8E7298-3B73-4415-B5F2-38DDCA12594F Q49561302-B91ED296-2CD8-4B51-8176-C6F9D20441FA Q50122599-D99B2EFC-5E7B-4323-88B7-6B3BFC4F1CD3 Q51736282-55B09B96-7BE9-451E-8F0F-CD96B5EE245F Q53047113-0C94813E-D59A-4C92-9D93-083735D5DED4 Q55334211-D1B3A40B-6A63-4EBA-A79A-E57E042C2BD2 Q56898750-F7202F2A-5FC2-4028-9412-7BD5C6640202

P2860

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

http://www.wikidata.org/entity/Q36070459

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Topical resiquimod can induce ...... s in cutaneous T-cell lymphoma

@ast

Topical resiquimod can induce ...... s in cutaneous T-cell lymphoma

@en

type

label

Topical resiquimod can induce ...... s in cutaneous T-cell lymphoma

@ast

Topical resiquimod can induce ...... s in cutaneous T-cell lymphoma

@en

prefLabel

Topical resiquimod can induce ...... s in cutaneous T-cell lymphoma

@ast

Topical resiquimod can induce ...... s in cutaneous T-cell lymphoma

@en

P1433

Q36070459-6DF5D776-0A71-446E-964B-EBFF0FBDB2D1

P1476

Q36070459-CDDB8F7B-EA14-4BFB-B1EC-BA4B311DFEC1

P2093

Q36070459-0FCDBDF5-9A9A-4B4C-90B2-2A6F1C296A06

Q36070459-1717A5F3-F00B-4FAC-A76A-7DB77D813520

Q36070459-25EAC5A2-2EFA-4EFB-988A-FB9EF7DA377E

Q36070459-3B62F5DB-AB42-4246-951E-0CF29628B7E3

Q36070459-477868CA-4A24-4319-9A67-30E5B5B40885

Q36070459-4E47DC15-BFA4-42C8-8D5A-C5A47A62C882

Q36070459-5324F817-4088-4056-B473-6B3688CFB89D

Q36070459-5D139638-1C2E-4B5C-921E-DD496355B719

Q36070459-BB460B6A-90D1-41C7-8F7C-FBF3450FE6D5

Q36070459-CA428C71-0EF3-4427-A54B-06E5DAF723C4

P2860

Q36070459-02D20542-567D-409E-973B-A94FE82F182D

Q36070459-0F5EAD6E-B1BF-4BE4-BFB7-2681C0D9626B

Q36070459-1D6890CA-3CA1-45F5-A28B-F54A4C622929

Q36070459-2BEC26FC-EF76-4B0A-82A7-A7A6E93A83DD

Q36070459-3E6A2328-6E07-4F26-8E08-FE29EA55D4BA

Q36070459-488D0CCB-5AF8-482B-B117-92F310BEE298

Q36070459-62771983-C07E-45BD-A94E-650B46BD31FE

Q36070459-6FC80A65-5FAD-41B6-97A3-2AC306A70AD3

Q36070459-819AC2BC-BD0D-4A31-AFC0-086DC3DD9ACE

Q36070459-8B0AE838-A6BB-4348-8619-6DA5C308CE3B

P304

Q36070459-691FEB1A-29A0-44D8-A837-2E66F1310262

P31

Q36070459-3C50B5C1-2C13-47BA-A0E1-F08F5FB73E26

P356

Q36070459-BE710CE6-E461-4CA7-87C7-AD6F740B576D

P407

Q36070459-E6A132EE-8931-49C6-9721-4D72E5744511

P433

Q36070459-838090B1-2E14-45DB-8720-41361BBE5151

P478

Q36070459-E37A31A9-7AC6-44B6-B195-17FEE81453F0

P50

Q36070459-02F25325-FF52-4249-97B2-4923C1E1C61D

Q36070459-45AED598-028E-4815-B522-7DDF7E3417A6

P577

Q36070459-D8B50711-8FD1-48AD-888D-C4B158F27AB6

P5875

Q36070459-FDC15907-2EF3-469D-B78A-901A9E6E4146

P698

Q36070459-05E2BE0B-A8B6-403F-B0CA-D440FF76934C

P932

Q36070459-30CF2847-1E5E-4282-BF9B-6279B35F10BA

P356

BLOOD-2015-02-630335

P1433

P1476

Topical resiquimod can induce ...... s in cutaneous T-cell lymphoma

@en

P2093

Alain H Rook

http://www.w3.org/2001/XMLSchema#string

Bernice Benoit

http://www.w3.org/2001/XMLSchema#string

Christian Surber

http://www.w3.org/2001/XMLSchema#string

Deborah S Leahy

http://www.w3.org/2001/XMLSchema#string

Ellen J Kim

http://www.w3.org/2001/XMLSchema#string

Ilan R Kirsch

http://www.w3.org/2001/XMLSchema#string

Maria Wysocka

http://www.w3.org/2001/XMLSchema#string

Marie A Buchanan

http://www.w3.org/2001/XMLSchema#string

Rachael A Clark

http://www.w3.org/2001/XMLSchema#string

Rei Watanabe

http://www.w3.org/2001/XMLSchema#string

P2860

Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.

IMGT, the international ImMunoGeneTics information system.

Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

WHO-EORTC classification for cutaneous lymphomas.

The pathogenesis of mycosis fungoides.

Treatment of cutaneous T cell lymphoma: current status and future directions.

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.

The small-molecule immune response modifier imiquimod--its mode of action and clinical use in the treatment of skin cancer.

P304

1452-1461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-02-630335

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

Andrea B Troxel

P577

2015-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280582459

http://www.w3.org/2001/XMLSchema#string

P698

26228486

http://www.w3.org/2001/XMLSchema#string

P932

4573868

http://www.w3.org/2001/XMLSchema#string